Leading the Way in Life Science Technologies

GEN Exclusives

More »

Sep. 1, Vol. 29, No. 15

      • Live-Cell Imaging Increases Impact on R&D
      • Gail Dutton
      • Live-cell imaging technologies are providing what is often the first detailed look at intracellular interactions within living cells, yielding fresh insights into molecular functions and dynamic structures that may change within fractions of a secon ... more »
      • MDx Hones In On Near-Patient Setting
      • Nina Flanagan
      • Molecular diagnostic advances are being driven by the need for automation and easy-to-handle techniques, said Mark Bunger, research director, biosciences at Lux Research. Longer-term trends also driving this market include the influx of smaller comp ... more »
      • Next-Gen Presents Array of Opportunities
      • Elizabeth Lipp
      • Next-generation sequencing (NGS) has arrived. “The expansion of users and applications shows no signs of abating,” notes Michael Rhodes, Ph.D., senior manager, SOLiD Sequencing at Applied Biosystems, a division of Life Technologies. “The uptick of t ... more »
      • Q&A on Sartorius Stedim Biotech/SAFC Deal
      • SAFC Biosciences and Sartorius Stedim Biotech recently signed a global partnership agreement that combines Sartorius Stedim Biotech’s expertise in filtration and liquid-handling systems with SAFC Biosciences’ proficiency in development and manu ... more »
    • Legal Affairs

    • Corporate Profile

      • EcoBiotics Scours Rainforest for Compounds
      • Carol Potera
      • Since 2000, EcoBiotics has been quietly combing the rainforests of Queensland, Australia, for new pharmaceutical compounds. Now with two anticancer candidates in the late stages of preclinical testing, the company is expanding to the U.S. and Europe ... more »
    • Tech Notes

      • Simplifying Antibody Conjugation Processes
      • Nick Gee,
      • Antibodies are widely employed in the quantification of antigens in complex biological samples. Using techniques such as Western blotting, ELISA, and immunohistochemistry researchers are able to measure a single antigen, or perhaps a limited number ... more »
    • Roundtable Discussions

      • Cellular Imaging and Analysis Roundtable
      • GEN recently sat down with thought leaders in the cellular imaging and analysis space to talk about current and emerging trends in the field. The three experts, all intimately familiar with imaging applications, talked about the use of high-content ... more »
    • Sidebars

      • Choosing the Right Model
      • In all areas of clinical testing, peptide-based therapeutics have dramatically increased, nearly doubling from 2000 to 2007,” says Ralf Brandt, Ph.D., CEO and managing director of vivoPharm. “However, many have failed due to lack of sufficient effic ... more »

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »